



**UvA-DARE (Digital Academic Repository)**

**Gene therapy in the cardiovascular system: editorial**

Levi, M.M.; Coronel, R.

*Published in:*  
Cardiovascular research

[Link to publication](#)

*Citation for published version (APA):*

Levi, M. M., & Coronel, R. (1997). Gene therapy in the cardiovascular system: editorial. *Cardiovascular research*, 35, 389-390.

**General rights**

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

**Disclaimer/Complaints regulations**

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <http://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

Editorial

## Gene Therapy in the Cardiovascular System

Marcel Levi<sup>a</sup>, Ruben Coronel<sup>b</sup>

<sup>a</sup> Center for Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

<sup>b</sup> Department of Experimental Cardiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

Cardiovascular disease is the leading cause of mortality in the Western world, and although major progress has been made in the prevention and management of cardiovascular diseases, currently available interventions are often insufficiently efficacious or associated with various adverse effects. Also, most therapies are directed at the consequences (e.g. ischemia) rather than the causes (e.g. atherosclerosis) of the disease. Novel therapies that much more specifically interfere in pathogenetic processes might be of great benefit for prevention and treatment of cardiovascular disorders and the underlying causes.

The transfer of genes into the somatic cells of patients (or: “gene therapy”) to interfere with pathogenetic processes contributing to cardiovascular disease may provide such a novel approach for better prevention and treatment of cardiovascular disorders [1,2]. Two major developments have importantly contributed to the intense investigation of the potential of gene therapy in cardiovascular medicine: First, the tremendous increment in knowledge on specific pathways and mediators that appear to play pivotal roles in the pathogenesis of cardiovascular disease has provided several therapeutic targets for specific intervention. Second, the amazing advances in molecular biology have provided a dramatic improvement of the technology that is necessary to clinically apply gene therapy.

Gene therapy for cardiovascular disorders is now fast developing and a considerable number of successful reports on the effects of gene transfer in various animal models are being published. Also, initial clinical studies are being developed or in progress. However, a large number of issues need to be resolved before this approach can further expand, and much research is currently devoted to solve these issues. Hence, the editorial team of *Cardiovascular Research* thought that it might be timely to devote a spotlight issue to the subject of “Gene Therapy in the Cardiovascular System”. Many thanks should be directed to the guest editors of this spotlight issue, Christophe Bauters, Peter Carmeliet and Hans Pannekoek, who were extremely helpful in soliciting contributions from various

outstanding researchers in the field for this special issue and in reviewing the various manuscripts.

This spotlight issue of *Cardiovascular Research* contains several reviews and original articles dealing with the potential and limitations of gene therapy, the identification of ideal genes to interfere with, optimal techniques for gene transfer and transduction of vascular cells and cardiomyocytes, application of gene therapy in different animal models, and potential clinical applications.

Optimal techniques for gene delivery in arteries and local drug delivery systems are being reviewed by Feldman and Steg [3] and by Brieger and Topol [4], and several original articles deal with various viral vectors for gene transfer [5–7]. One of the important limitations of viral gene transfer may be the immunological response to the viral vector. Yap et al. [8] describe how immunosuppression may partly overcome this response. Gene transfer may be helpful for inherited or acquired diseases of the heart, as reviewed in this issue [9,10], and further illustrated by two original contributions [11,12]. A major point of impact for gene therapy is represented by atherothrombotic vascular diseases: Subsequently, the potential of gene therapy for treatment of hypercholesterolemia, arterial thrombosis, and restenosis are reviewed [13–15]. In addition, reports of original studies on transfection of endothelial cells [16], and transfer of the nitric oxide synthase gene, the vascular endothelial growth factor gene, or the GAX gene [17–19], are included. Finally, the subject of gene transfer-induced therapeutic angiogenesis is highlighted in two review articles [20,21].

In summary, this issue of *Cardiovascular Research* reflects the exciting development of gene therapy for a broad spectrum of disorders in the cardiovascular system. Whether these novel therapeutic approaches will be as successful as they promise to be remains to be seen in appropriate clinical trials. However, the exploration of gene transfer in various areas of cardiovascular research will certainly yield an enormous enhancement of the insights in pathogenesis and therapeutic targets in cardio-

vascular disease and the possibilities of molecular genetic technologies in cardiovascular medicine.

## References

- [1] Hamsten A. Molecular genetics as the route to understanding, prevention and treatment. *Lancet* 1996;348(suppl):s17–9.
- [2] Nabel EG. Gene therapy for cardiovascular disease. *Circulation* 1995;91:541–548.
- [3] Feldman LJ, Steg G. Optimal techniques for arterial gene transfer. *Cardiovasc Res* 1997;35:391–404.
- [4] Brieger D, Topol E. Local drug delivery systems and prevention of restenosis. *Cardiovasc Res* 1997;35:405–413.
- [5] Roks AJM, Pinto YM, Paul M, et al. Vectors based on Semliki Forest virus for rapid and efficient gene transfer into non-endothelial cardiovascular cells: comparison to adenovirus. *Cardiovasc Res* 1997;35:498–504.
- [6] Channon KM, Fulton GJ, Gray JL, et al. Efficient adenoviral gene transfer to venous bypass grafts: comparison with native vessels. *Cardiovasc Res* 1997;35:505–513.
- [7] Maeda Y, Ikeda U, Ogasawara Y, et al. Gene transfer into vascular cells using adeno-associated virus (AAV) vectors. *Cardiovasc Res* 1997;35:514–521.
- [8] Yap J, O'Brien T, Tazelaar HD, McGregor CGA. Immunosuppression prolongs adenoviral mediated transgene expression in cardiac allograft transplantation. *Cardiovasc Res* 1997;35:529–535.
- [9] Bowles NE, Wang Q, Towbin JA. Prospects for adenovirus-mediated gene therapy of inherited diseases of the myocardium. *Cardiovasc Res* 1997;35:422–430.
- [10] Leor J, Prentice H, Sartorelli V, et al. Gene transfer and cell transplant: an experimental approach to repair a 'broken heart'. *Cardiovasc Res* 1997;35:431–441.
- [11] Franz WM, Rothmann T, Frey N, Katus H. Analysis of tissue-specific gene delivery by recombinant adenoviruses containing cardiac-specific promoters. *Cardiovasc Res* 1997;35:560–566.
- [12] Prentice H, Bishopric N, Hicks MN, et al. Regulated expression of a foreign gene targeted to the ischaemic myocardium. *Cardiovasc Res* 1997;35:567–574.
- [13] Vassalli G, Dichek DA. Gene therapy for arterial thrombosis. *Cardiovasc Res* 1997;35:459–469.
- [14] Gerard R, Collen D. Adenovirus gene therapy for hypercholesterolemia, thrombosis and restenosis. *Cardiovasc Res* 1997;35:451–458.
- [15] Baker AH, Mehta D, George SJ, Angelini GD. Prevention of vein graft failure: potential applications for gene therapy. *Cardiovasc Res* 1997;35:442–450.
- [16] Tanner FC, Carr DP, Nabel GJ, Nabel EG. Transfection of human endothelial cells. *Cardiovasc Res* 1997;35:522–528.
- [17] Cable DG, O'Brien T, Kullo IJ, et al. Expression and function of a recombinant endothelial nitric oxide synthase gene in porcine coronary arteries. *Cardiovasc Res* 1997;35:553–559.
- [18] Takeshita S, Isshiki T, Mori H, et al. Microangiographic assessment of collateral vessel formation following direct gene transfer of vascular endothelial growth factor in rats. *Cardiovasc Res* 1997;35:547–552.
- [19] Maillard L, van Belle E, Smith RC, et al. Percutaneous delivery of the *gax* gene inhibits vessel stenosis in a rabbit model of balloon angioplasty. *Cardiovasc Res* 1997;35:536–546.
- [20] Melillo G, Scocianti M, Kovessi I, et al. Gene therapy for collateral vessel development. *Cardiovasc Res* 1997;35:480–489.
- [21] Lewis BS, Flugelman MY, Weisz A, Keren-Tal I, Schaper W. Angiogenesis by gene therapy: a new horizon for myocardial revascularization?. *Cardiovasc Res* 1997;35:490–497.